Frequency Therapeutics
The business, the turning points, and the decisions behind them.
01 / WHAT IT BUILT
What the company did
Frequency Therapeutics was a regenerative medicine biotech company based in Lexington, Massachusetts, listed on Nasdaq as FREQ. Founded to develop drugs that stimulate the body's own progenitor cells to restore function, its lead program FX-322 was an injectable treatment for acquired sensorineural hearing loss, alongside a second program FX-345. The company raised about $180 million.
02 / Frequency Therapeutics FAILURE REASONS
Failure factors
Frequency Therapeutics' 13 Feb 2023 release (via BioSpace/Business Wire) stated Phase 2b FX-322 for sensorineural hearing loss failed its primary speech-perception endpoint with no meaningful difference vs placebo; company discontinued FX-322 and FX-345 hearing programs and cut ~55% of staff—clinical failure driving program wind-down.
FX-322 Phase 2b failed primary efficacy endpoint (speech perception) vs placebo.
Company discontinued FX-322 and second hearing candidate FX-345.
03 / EVENT HISTORY
Events in the structured record
- Operations ended
Korro Bio / Frequency announced closing of merger and $117M private placement; combined company trades as KRRO—Frequency Therapeutics as independent hearing biotech ended.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
In February 2023 the Phase 2b study of FX-322 failed: the drug showed no statistically significant improvement in speech perception over placebo, missing all primary and secondary endpoints.
- 02
Frequency discontinued both the FX-322 program and its second hearing program FX-345.
- 03
The company cut about 55% of its workforce, completed by April 2023, and pivoted remaining resources to a remyelination program for multiple sclerosis, with runway said to extend into 2025.
- 04
No reliable loss figure with a clear subject, period and basis exists, so no loss amount is recorded.